JP6880037B2 - がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 - Google Patents

がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 Download PDF

Info

Publication number
JP6880037B2
JP6880037B2 JP2018535307A JP2018535307A JP6880037B2 JP 6880037 B2 JP6880037 B2 JP 6880037B2 JP 2018535307 A JP2018535307 A JP 2018535307A JP 2018535307 A JP2018535307 A JP 2018535307A JP 6880037 B2 JP6880037 B2 JP 6880037B2
Authority
JP
Japan
Prior art keywords
biomarker
compound
sample
cancer
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018535307A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019504063A5 (enExample
JP2019504063A (ja
Inventor
フィルバロフフ エレン
フィルバロフフ エレン
ロペス‐ジロナ アントニア
ロペス‐ジロナ アントニア
ル ガング
ル ガング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2019504063A publication Critical patent/JP2019504063A/ja
Publication of JP2019504063A5 publication Critical patent/JP2019504063A5/ja
Priority to JP2021077686A priority Critical patent/JP7113942B2/ja
Application granted granted Critical
Publication of JP6880037B2 publication Critical patent/JP6880037B2/ja
Priority to JP2022118437A priority patent/JP2022166014A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2018535307A 2016-01-08 2017-01-06 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 Active JP6880037B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021077686A JP7113942B2 (ja) 2016-01-08 2021-04-30 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2022118437A JP2022166014A (ja) 2016-01-08 2022-07-26 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276700P 2016-01-08 2016-01-08
US62/276,700 2016-01-08
US201662404638P 2016-10-05 2016-10-05
US62/404,638 2016-10-05
PCT/US2017/012496 WO2017120446A1 (en) 2016-01-08 2017-01-06 Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021077686A Division JP7113942B2 (ja) 2016-01-08 2021-04-30 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用

Publications (3)

Publication Number Publication Date
JP2019504063A JP2019504063A (ja) 2019-02-14
JP2019504063A5 JP2019504063A5 (enExample) 2020-02-27
JP6880037B2 true JP6880037B2 (ja) 2021-06-02

Family

ID=59274055

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018535307A Active JP6880037B2 (ja) 2016-01-08 2017-01-06 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2021077686A Active JP7113942B2 (ja) 2016-01-08 2021-04-30 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2022118437A Pending JP2022166014A (ja) 2016-01-08 2022-07-26 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021077686A Active JP7113942B2 (ja) 2016-01-08 2021-04-30 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用
JP2022118437A Pending JP2022166014A (ja) 2016-01-08 2022-07-26 がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用

Country Status (10)

Country Link
US (3) US10648983B2 (enExample)
EP (1) EP3399980B1 (enExample)
JP (3) JP6880037B2 (enExample)
KR (1) KR20180095094A (enExample)
AU (1) AU2017205170B2 (enExample)
CA (1) CA3010801A1 (enExample)
ES (1) ES3042541T3 (enExample)
IL (2) IL296659A (enExample)
MX (1) MX390772B (enExample)
WO (1) WO2017120446A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
AU2016326499A1 (en) 2015-09-25 2018-04-12 Celgene Corporation Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
WO2019121869A1 (en) * 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of selection of an ire1-inhibitor therapy for patient suffering from cancer
US10584133B2 (en) 2018-03-30 2020-03-10 Biotheryx, Inc. Thienopyrimidinone compounds
IL278854B2 (en) * 2018-05-23 2026-01-01 Celgene Corp Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN114761400B (zh) * 2019-09-12 2024-08-13 南京明德新药研发有限公司 一种可降解蛋白的并环类化合物及其应用
BR112022007996A2 (pt) * 2019-10-28 2022-07-05 Celgene Corp Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
US20220378773A1 (en) * 2019-10-28 2022-12-01 Celgene Corporation Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies
US11031119B2 (en) * 2019-11-13 2021-06-08 Cube Click, Inc. Dental images processed with deep learning for national security
IL293481A (en) * 2019-12-06 2022-08-01 Celgene Corp Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
KR102311390B1 (ko) * 2020-03-03 2021-10-13 이화여자대학교 산학협력단 교모세포종 예후예측용 조성물
US20230149379A1 (en) * 2020-03-16 2023-05-18 Celgene Corporation Combination therapy for acute myeloid leukemia
WO2021211742A1 (en) * 2020-04-14 2021-10-21 The General Hospital Corporation Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction
WO2021260110A1 (en) 2020-06-25 2021-12-30 Tolremo Therapeutics Ag Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
AU2021298154A1 (en) 2020-06-25 2023-02-23 Tolremo Therapeutics Ag Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
CN117242060B (zh) 2021-01-13 2026-07-17 蒙特罗莎治疗股份有限公司 异吲哚啉酮化合物
WO2022152822A1 (en) * 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Treatment of myc-driven cancers with gspt1 degraders
GB202104635D0 (en) * 2021-03-31 2021-05-12 Imperial College Innovations Ltd Methods and compositions for identifying and treating GCN2-dependent cancers
CA3212085C (en) * 2021-04-07 2025-02-11 Tolremo Therapeutics Ag HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER
WO2022219412A1 (en) * 2021-04-14 2022-10-20 Monte Rosa Therapeutics Ag Isoindolinone amide compounds useful to treat diseases associated with gspt1
WO2023085785A1 (ko) 2021-11-09 2023-05-19 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
KR102823538B1 (ko) 2021-11-09 2025-06-23 한국화학연구원 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도
CN114660289A (zh) * 2022-03-03 2022-06-24 中山大学附属第三医院 肝癌标志物及其应用
EP4508044A1 (en) * 2022-04-14 2025-02-19 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
US20240115557A1 (en) * 2022-07-29 2024-04-11 The Brigham And Women's Hospital, Inc. Inhibitors of rna-guided nucleases and uses thereof
EP4581014A1 (en) * 2022-09-02 2025-07-09 Deciphera Pharmaceuticals, LLC Ulk inhibitors and methods of use thereof
CN120322242A (zh) * 2022-09-16 2025-07-15 联邦高等教育系统天普大学 Bag3用于治疗心脏淀粉样变性的方法和用途
KR20240066906A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR20240066904A (ko) 2022-11-08 2024-05-16 주식회사 온코드바이오 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
KR102570883B1 (ko) * 2023-04-13 2023-08-29 (주) 사이러스테라퓨틱스 신규한 gspt1 분해제 및 이의 용도
WO2025164957A1 (ko) * 2024-01-31 2025-08-07 남부대학교산학협력단 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1574740A (en) * 1924-04-07 1926-02-23 Raynor John Roscoe Cutting device
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1993018186A1 (en) 1992-03-04 1993-09-16 The Regents Of The University Of California Comparative genomic hybridization (cgh)
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
EP0946169B1 (en) 1996-12-20 2003-02-26 Takeda Chemical Industries, Ltd. Method of producing a sustained-release preparation
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
GB0103527D0 (en) 2001-02-13 2001-03-28 Eastman Kodak Co Photographic developing composition and use thereof in the development of a photographic element
US7122799B2 (en) 2003-12-18 2006-10-17 Palo Alto Research Center Incorporated LED or laser enabled real-time PCR system and spectrophotometer
MX2007014537A (es) * 2005-05-18 2008-02-12 Wyeth Corp Genes de la enfermedad de la leucemia y sus usos.
CA2957226C (en) 2008-10-29 2018-08-14 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
TWI509247B (zh) 2010-03-12 2015-11-21 西建公司 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
EP2699091B1 (en) 2011-03-28 2017-06-21 DeuteRx, LLC 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012149299A2 (en) 2011-04-29 2012-11-01 Celgene Corporaiton Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
WO2014179661A1 (en) * 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
BR112016012792A2 (pt) 2013-12-06 2017-08-08 Celgene Corp Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras
US9499514B2 (en) * 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
JP2017533727A (ja) 2014-10-13 2017-11-16 セルジーン コーポレイション 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用
WO2016196580A1 (en) 2015-06-02 2016-12-08 Celgene Corporation Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins
US20170038387A1 (en) 2015-08-04 2017-02-09 Celgene Corporation Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
US20180231561A1 (en) 2015-08-12 2018-08-16 Celgene Corporation Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
AU2016326499A1 (en) 2015-09-25 2018-04-12 Celgene Corporation Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
CA3010794A1 (en) * 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3399980B1 (en) 2016-01-08 2025-07-16 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
US10052315B2 (en) * 2016-01-08 2018-08-21 Celgene Corporation Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
SG11201809501PA (en) * 2016-06-06 2018-12-28 Celgene Corp Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide

Also Published As

Publication number Publication date
JP7113942B2 (ja) 2022-08-05
EP3399980A4 (en) 2019-09-04
EP3399980A1 (en) 2018-11-14
ES3042541T3 (en) 2025-11-21
US20230064156A1 (en) 2023-03-02
JP2019504063A (ja) 2019-02-14
JP2021121799A (ja) 2021-08-26
AU2017205170B2 (en) 2021-06-24
CA3010801A1 (en) 2017-07-13
IL260400B (en) 2022-10-01
MX390772B (es) 2025-03-21
MX2018008421A (es) 2019-12-09
EP3399980B1 (en) 2025-07-16
AU2017205170A1 (en) 2018-07-19
US11460471B2 (en) 2022-10-04
WO2017120446A1 (en) 2017-07-13
JP2022166014A (ja) 2022-11-01
KR20180095094A (ko) 2018-08-24
US20170199193A1 (en) 2017-07-13
IL260400A (enExample) 2018-08-30
US12474342B2 (en) 2025-11-18
US10648983B2 (en) 2020-05-12
US20200333340A1 (en) 2020-10-22
IL296659A (en) 2022-11-01
IL260400B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US12474342B2 (en) Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
JP2019504063A5 (enExample)
JP7853352B2 (ja) 多発性骨髄腫を治療すること及び４－（４－（４－（（（２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－４－イル）オキシ）メチル）ベンジル）ピペラジン－１－イル）－３－フルオロベンゾニトリルのバイオマーカーの使用
US20180267043A1 (en) Use of biomarkers for predicting clinical sensitivity to cancer treatment
KR102299801B1 (ko) 미만성 거대 b-세포 림프종, 다발성 골수종, 및 골수암의 치료를 위한 약물 효능을 결정하는 방법
JP6585737B2 (ja) セレブロン関連タンパク質の比を使用してがんの治療のための薬物の有効性を決定するための方法
KR20180052747A (ko) 미만성 거대 b세포 림프종의 치료 방법 및 약물에 대한 반응성의 예측자로서 바이오마커의 용도
KR20230079171A (ko) 전신 홍반성 루푸스의 치료 방법 및 치료법에 대한 임상적 민감도의 예측인자로서의 바이오마커의 용도

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191226

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20191226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210406

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210430

R150 Certificate of patent or registration of utility model

Ref document number: 6880037

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250